204 related articles for article (PubMed ID: 35910351)
1. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
Long H; Yang Y; Geng X; Mao Z; Mao Z
Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
[No Abstract] [Full Text] [Related]
2. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.
Lu J; Long H; Shen Y; Wang J; Geng X; Yang Y; Mao Z; Li J
Front Pharmacol; 2022; 13():923209. PubMed ID: 36081942
[No Abstract] [Full Text] [Related]
3. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
Wang N; Yang Y; Xu L; Mao Z; Cui D
BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
[TBL] [Abstract][Full Text] [Related]
4. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
5. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
[TBL] [Abstract][Full Text] [Related]
6. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
7. Impact of '4+7' volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China.
Wang J; Yang Y; Xu L; Shen Y; Wen X; Mao L; Wang Q; Cui D; Mao Z
BMJ Open; 2022 Mar; 12(3):e054346. PubMed ID: 35288385
[TBL] [Abstract][Full Text] [Related]
8. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.
Yang Y; Hu R; Geng X; Mao L; Wen X; Wang Z; Hao S; Cui D; Mao Z
Int J Health Plann Manage; 2022 May; 37(3):1650-1662. PubMed ID: 35132676
[TBL] [Abstract][Full Text] [Related]
9. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
Yang Y; Chen L; Ke X; Mao Z; Zheng B
BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
[TBL] [Abstract][Full Text] [Related]
10. The impacts of national centralized drug procurement policy on drug utilization of medical institutions: an empirical study in a county-level hospital in China.
Li H; Lin F; Wang R; Zhu C; Cao K; Chen Y; Fang G; Li J; Ding J; Li W
BMC Health Serv Res; 2024 Apr; 24(1):513. PubMed ID: 38658940
[TBL] [Abstract][Full Text] [Related]
11. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
[No Abstract] [Full Text] [Related]
12. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis.
Rong X; Yin J; Duan S; Sun Q; Babar ZU
BMC Public Health; 2020 Apr; 20(1):588. PubMed ID: 32349722
[TBL] [Abstract][Full Text] [Related]
13. The Impacts of National Centralized Drug Procurement Policy on Drug Utilization and Drug Expenditures: The Case of Shenzhen, China.
Chen L; Yang Y; Luo M; Hu B; Yin S; Mao Z
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33334027
[TBL] [Abstract][Full Text] [Related]
14. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
15. The impact of Chinese volume-based procurement on pharmaceutical market concentration.
Yang Y; Liu Y; Mao Z; Mao J; Jin Y
Front Pharmacol; 2024; 15():1386533. PubMed ID: 38895618
[TBL] [Abstract][Full Text] [Related]
16. Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China.
Li Z; Liu C; Zuo K; Liu J; Tang Y
Front Pharmacol; 2021; 12():741671. PubMed ID: 34721029
[No Abstract] [Full Text] [Related]
17. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls.
Chen Y; Ji X; Xiao H; Unger JM; Cai Y; Mao Z; Yeung K
Front Pharmacol; 2021; 12():804237. PubMed ID: 35815118
[TBL] [Abstract][Full Text] [Related]
18. Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study.
Sun Z; Na X; Chu S
Front Public Health; 2023; 11():1227102. PubMed ID: 38026347
[TBL] [Abstract][Full Text] [Related]
19. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis.
Wen X; Yin S; Cui L; Mao L; Lin Z; Yaermaimaiti Z; Geng X; Li Y; Yang Y; Cui D; Mao Z
Front Public Health; 2021; 9():718013. PubMed ID: 34760861
[No Abstract] [Full Text] [Related]
20. The impacts of the national centralized drug procurement policy on the use of policy-related antibiotic agents: the case of Shaanxi province, China.
Yang C; Ye D; Yan K; Xiang C; Liu S; Gu J; Liu Y; Fang Y
Expert Rev Anti Infect Ther; 2023 Jun; 21(6):675-684. PubMed ID: 37013799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
